Conversely, the prevalence of HER2 overexpression is decreased in cases of uterine, pancreatic, and head and neck cancers, and HER2 is generally not expressed in kidney or liver cancers, illustrating a complex pattern of expression that affects therapeutic decisions and outcomes across various cancer types (Hsu et al., 2002; Randall et al., 2024; Wang et al., 2012, 2020a; Warren et al., 2021). This evidence concerns the gene ERBB2 and cancer.